Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients

Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients

Related Keywords

China ,United States ,Uzbekistan ,United Kingdom ,Jianjun ,Shaanxi ,Beijing ,Guangzhou ,Guangdong ,Maryland ,Suzhou ,Jiangsu ,San Francisco ,California ,Shanghai ,Chinese ,Zhi Li ,Junshi Bioscience ,Junshi Biosciences ,Regulatory Agency ,Global Research ,National Reimbursement Drug List ,Data Monitoring Committee ,Drug Administration ,Pr Team ,Ir Team ,World Health Organization ,European Medicines Agency ,National Medical Products Administration ,Shanghai Junshi Biosciences Co Ltd ,Junshi Biosciences Announces Acceptance ,Supplemental New Drug Application ,Perioperative Treatment ,Professor Shun ,Shanghai Chest Hospital ,Independent Data Monitoring Committee ,Southeast Asia ,Biologics License Application ,Breakthrough Therapy ,Fast Track ,Orphan Drug ,Emergency Use Authorizations ,Investegate Announcements ,Investegate Company Announcements ,Lobenewswire ,Lobenewswire And Globenewswire ,Nw ,